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Abstract
Cell–cell adhesions constitute the structural “glue” that retains cells together and contributes to tissue organisation
and physiological function. The integrity of these structures is regulated by extracellular and intracellular signals and
pathways that act on the functional units of cell adhesion such as the cell adhesion molecules/adhesion receptors, the
extracellular matrix (ECM) proteins and the cytoplasmic plaque/peripheral membrane proteins. In advanced cancer,
these regulatory pathways are dysregulated and lead to cell–cell adhesion disassembly, increased invasion and
metastasis. The Metastasis suppressor protein 1 (MTSS1) plays a key role in the maintenance of cell–cell adhesions and
its loss correlates with tumour progression in a variety of cancers. However, the mechanisms that regulate its function
are not well-known. Using a system biology approach, we unravelled potential interacting partners of MTSS1. We
found that the secretory carrier-associated membrane protein 1 (SCAMP1), a molecule involved in post-Golgi recycling
pathways and in endosome cell membrane recycling, enhances Mtss1 anti-invasive function in HER2+/ER−/PR−
breast cancer, by promoting its protein trafﬁcking leading to elevated levels of RAC1-GTP and increased cell–cell
adhesions. This was clinically tested in HER2 breast cancer tissue and shown that loss of MTSS1 and SCAMP1 correlates
with reduced disease-speciﬁc survival. In summary, we provide evidence of the cooperative roles of MTSS1 and
SCAMP1 in preventing HER2+/ER−/PR− breast cancer invasion and we show that the loss of Mtss1 and Scamp1
results in a more aggressive cancer cell phenotype.
Introduction
Metastasis is a process by which cancer cells that
acquired high migratory and invasive properties, leave
primary tumours and migrate through the vascular and
lymphatic circulatory system to other tissues where they
form secondary tumours1. This process requires the
inactivation of cellular and molecular pathways that
maintain cell–cell adhesion and regulate cytoskeleton
remodelling and cell motility2. In breast cancer 1:5
women have tumours that over express the epidermal
growth factor receptor 2 (HER2)/Neu) protein due to
ampliﬁcation of the oncogenic ERBB2 gene. HER2-
positive (HER2+) tumours are among the most aggres-
sive and metastatic3,4. The protein Her2 is a member of
the epidermal growth factor receptor family. HER2 pro-
motes cell proliferation and survival through the induc-
tion of signalling cascades that involve RAS signalling
pathways. In this study, we have used a system biology
approach to predict RAS interactome pathways from
interrogation of a publically available HER2+ breast
cancer gene expression array data set. We found that the
Metastasis suppressor protein 1 (MTSS1) forms a strong
hub of connectivity with other genes that are also sig-
niﬁcantly expressed in this microarray data set.
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MTSS1 belongs to the IMD-family (IRSp53 and MIM
(Missing in metastasis) domain) and serves as an actin-
binding scaffold protein that is implicated in carcinogen-
esis and metastasis. It has been proposed that MTSS1
promotes the assembly of actin ﬁlaments, and is associated
with cytoskeletal organisation and cell motility through
elevating RAC1-GTP expression5–7. This effect accelerates
the kinetics of adherens junction assembly and therefore
cell–cell adhesions7. MTSS1 is highly expressed in some
cancer types and its loss correlates with metastasis and
poor prognosis, including breast cancer8,9. However, the
mechanisms and molecular pathways that regulate the
function of MTSS1 are less known. Analysis of the MTSS1
hub of connectivity unravelled several potential interacting
partners including the secretory carrier-associated mem-
brane protein 1 (SCAMP1). This molecule belongs to a
family of membrane proteins that are involved in post-
Golgi recycling pathways and endosome cell membrane
recycling10,11. The intracellular trafﬁcking of membrane
vesicles plays an essential role in the maintenance and the
regulation of components of the plasma membrane.
Alterations in this cellular pathway can affect cell–cell
adhesions and may result in increased cell motility and
invasion of cancer cells12. On the basis of this background,
we hypothesised that the vesicle carrier protein SCAMP1
is involved in stabilising MTSS1 protein trafﬁcking that
promotes MTSS1 anti-invasive and anti-metastatic func-
tions by endorsing cell–cell adhesion in HER2+ breast
cancer. Moreover, we reveal the dual role of MTSS1 and
SCAMP1 in preventing HER2+ breast cancer progression.
To better understand the role of MTSS1 and SCAMP1 in
tumour progression, we investigated their inﬂuence on cell
migration and invasion using HER2+ breast cancer cell
lines, and MTSS1-expressing and SCAMP1-expressing
constructs. Furthermore, we determined the translational
importance of this proposal in a clinical setting by showing
that loss of MTSS1 and SCAMP1 expression are speciﬁ-
cally associated with a worse prognosis in HER2+/ER
−/PR− breast cancer. These studies demonstrate that
MTSS1, via the carrier protein SCAMP1, prevents cell
invasion by promoting cell–cell adhesion via the induction
of elevated levels of RAC1-GTP. Collectively, these results
support the concept that SCAMP1 promotes MTSS1
protein trafﬁcking that potentiate anti-invasive and anti-
metastatic functions. SCAMP1-regulated MTSS1 prevents
a more aggressive cancer cell phenotype and its loss is
responsible for reduced survival in patients with HER2
+/ER−/PR− breast cancer.
Results
Identiﬁcation of MTSS1 and SCAMP1 as key regulators
of HER2+ cancer progression by artiﬁcial neural network
(ANN)-based integrative data mining HER2+ breast can-
cers are among the most aggressive type of breast cancer.
The HER2 receptor is activated upon ligand binding and
mediate their inﬂuence via RAS signalling pathways that
are involved in the regulation of cellular processes
including proliferation, survival, and migration. In HER2+
breast cancer, ERBB2 is mutated and results in aberrant
activation of RAS signalling that drives HER2+ breast
cancer progression. Due to the importance of this pathway,
we investigated cellular pathways that may contribute to
malignancy progression using a system biology approach.
A stepwise ANNmethod was used to identify an optimised
gene signature panel that is associated with the expression
of RAS in a HER2+ population from the Uppsala breast
cancer data set (E-GEOD 20194) (Fig. 1a). The top 100
most associated genes (out of 53,000) were selected for
ANN inference (ANNi) that uses a suite of ANN models to
study the inter-relationship between markers in a deﬁned
set based on the weights of the neural network model13,14.
Results of the full network inference with ﬁltering to the
top 100 interaction values are presented in cytoscape
(Fig. 1b and supplementary ﬁgure 1). The key hubs (genes
with the strongest level of interaction) identiﬁed were
MTSS1, KRT35, NTRK2, SLC6A2 and COL4A4 (Supple-
mentary ﬁgure 1). A predominance of strong positive
interactions are seen with fewer negative interactions.
Interestingly, MTSS1 has previously been shown to play a
key role in preventing invasion and metastasis in different
types of cancer9,15–22, but the mechanisms that regulate its
function are unknown. This bioinformatics approach
allowed the unravelling of potential interacting partners
that may regulate the function of MTSS1 (Fig. 1b).
Among MTSS1-predicted interacting partners, we
selected two molecules for further studies: SCAMP1 and
SERPIN B13. The SCAMP1 is a molecule that is involved
in post-Golgi recycling pathways and in endosome cell
membrane recycling10,11. During these processes, some
proteins (e.g., receptors) are a target of proteolysis invol-
ving proteinases such as Cathepsins that are involved in
endosomal protein catabolism. SERPIN B13 (Hurpin/
Headpin) is an intracellular inhibitor of papain-like
cysteine proteases (Cathepsins) that has been shown to
inhibit speciﬁcally Cathepsin K and L23,24. We further
hypothesised that SCAMP1 may act as a vesicular carrier
for MTSS1 and that SERPIN B13 may protect MTSS1
from potential proteolysis during endosome trafﬁcking.
Clinical signiﬁcance of MTSS1 and SCAMP1 expression:
association with poor prognosis
To investigate whether this hypothesis is translated in
the clinical setting, we veriﬁed the presence and the
expression of MTSS1, SCAMP1 and SERPIN B13 in a
cohort of breast cancer patients by immunohistochem-
istry staining, using speciﬁc antibodies to these proteins.
When present, cytoplasmic staining was detected in the
malignant breast tissue epithelium, with occasional
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membranous-type staining seen for SCAMP1 and SER-
PIN B13 (Fig. 2). Expression varied according to tumour
molecular phenotype with 73%, 16 and 11% Mtss1
expression seen in oestrogen receptor (ER)-positive, ER-
negative and HER2+ patient classes, respectively (χ2=
25.84, p < 0.0001). Across the whole (unselected) popu-
lation, MTSS1 expression did not associate with cancer-
speciﬁc survival (Supplementary ﬁgure 2A), but a rela-
tionship was detected with MTSS1 loss and metastasis
development (χ2= 3.83, p= 0.05).
Subgroup analysis was performed to test the relation-
ship of MTSS1 expression with disease-speciﬁc survival
and metastasis outcome in HER2+ breast cancer.
Expression of MTSS1 positively correlated with cancer
survival (χ2= 5.81, p= 0.016). Our in vitro studies
demonstrated a stronger inﬂuence of MTSS1 loss with
increasing tumour aggression in cancer cells with a ‘pure’
HER2+ phenotype (HER2+/ER−/PR−). In the clinical
samples, 52% of the HER2+ patient class had the HER2
+/ER−/PR− phenotype and they differed to their hor-
monally (ER/PR)-positive counterparts in showing
increased loss of MTSS1 (p= 0.031; Fig. 2g). HER2+/ER
−/PR− phenotype tumours showed increased loss of
SCAMP1 protein compared to other HER2+ classes (p=
0.034). In addition, a signiﬁcant positive correlation (r=
0.224, p= 0.013) between MTSS1 and SCAMP1 expres-
sion was identiﬁed in the ‘pure’ HER2 group but not in the
full patient cohort (Fig. 3).
Expression of MTSS1 and SCAMP1 prevent cell migration
and invasion
MTSS1 and SCAMP1 loss is associated with increased
invasion that is an early event of the metastatic process
and, as seen in the clinical samples, by worsened prog-
nosis. To investigate the expression of endogenous
MTSS1 and SCAMP1 in breast cancer cell lines, we
performed immunoblotting (IB) using whole-cell extracts
from SkBr3 and MDA-MB-453 (HER2+/ER−/PR−) and
BT-474 (HER2+/ER+/PR+) human breast cancer cells.
Compared to their expression in BT-474 (used as a con-
trol), SkBr3 and MDA-MB-453 expressed signiﬁcantly
lower levels of MTSS1 and SCAMP1 (Fig. 4a). This result
was consistent with the low expression of MTSS1 and
SCAMP1 that were observed in HER2+/ER−/PR− breast
cancer tissues (Fig. 2). To determine whether MTSS1 and
SCAMP1 interact, we performed a proximity ligation
assay (PLA) and immunoprecipitation (IP) experiment
using whole-cell extracts from the BT-474 breast cancer
cell line. The results from these experiments demon-
strated that both proteins interact (Fig. 4b, c).To investi-
gate the role of MTSS1 and SCAMP1 in cell migration
and invasion, we generated MTSS1 green ﬂuorescent
protein (GFP)-tagged and a SCAMP1 haemagglutinin
(HA)-tagged constructs: MTSS1-GFP and SCAMP1-HA
(Fig. 4a). The constructs were transfected in SkBr3 and
MDA-MB-453 cell lines and their protein expression
pattern was determined by IB and immunoﬂuorescence
(IF) (Fig. 4d, e). To determine the role of MTSS1 and
SCAMP1 in cell migration and invasion, we used a
wound-healing (Scratch assay) and well-cell invasion
assays. SkBr3 and MDA-MB-453 cells expressing MTSS1
or SCAMP1 exhibited a decreased migration (Fig. 5a, b)
and invasive (Fig. 5d, e) capacities in comparison to cells
expressing the empty vector (Fig. 5). This effect on
migration and invasion was more signiﬁcant when both
MTSS1 and SCAMP1 were co-expressed. An increased
Fig. 1 Snapshot of RAS interactome in HER2-positive breast cancer using a system biology approach. a Flowchart depicting the multi-tier
selection approach for identiﬁcation of RAS interactome. b Pathways of interest are highlighted by rectangles. Red arrows represent a positive
regulation and the blues a negative regulation
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cell migration of BT-474 breast cancer cells was also
observed following combined MTSS1 and SCAMP1
knockdowns, and when compared to the control or when
MTSS1 or SCAMP1 were individually knocked down
(Fig. 5c and supplementary ﬁgure 2B and C). Further-
more, the expression of MTSS1, SCAMP1 or both does
not appear to affect the proliferation of transfected cells
(Fig. 5f, g). These results demonstrate that MTSS1 and
SCAMP1 interact and cooperate in preventing migration
and invasion of HER2+/ER−/PR− breast cancer cells.
MTSS1 and SCAMP1 promote cell–cell adhesion via RAC1-
GTP activation in HER2+ breast cancer cell lines
The transition from non-invasive to invasive cancer is
prevented by cell–cell adhesions that are maintained by
collective actions of cellular pathways such as the ones
Fig. 2 Cytoplasmic staining was detected for (a) MTSS1, (b) SCAMP1 and (c) Serpin B13 protein in the malignant epithelium of breast cancer.
Alternatively, the majority of ‘pure’ HER2+ (HER2+/ER−/PR−) tumours showed loss or in (d) MTSS1, (e) SCAMP1 and (f) SERPIN B13 staining. g
Distribution of MTSS1, SCAMP1 and SERPIN B13 in the ‘pure’ HER2 patient class versus other tumour classes
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involved in the dynamic reorganisation of the actin cytos-
keleton. It has previously been shown that MTSS1 accel-
erate the kinetics of adherens junction assembly and
cell–cell adhesions through elevating RAC1-GTP expres-
sion5–7. To investigate the mechanism by which MTSS1
and Scamp1 prevent HER2+/ER−/PR− cell invasion, we
Fig. 3 Kaplan–Meier models of survival and metastasis development for MTSS1 (a, b), SCAMP1 (c, d) and SERPIN B13 (e, f) loss, respectively. Less
favourable prognosis is seen in patients with ‘pure’ HER2+ tumours compared to other patients showing loss of these biomarkers. Scale bar= 100 μm
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performed IF staining using Phalloidin (F-actin staining)
and antibodies for GFP and HA on cells that were trans-
fected with MTSS1-GFP and SCAMP1-HA. Increased
cell–cell contacts that are shown by F-actin staining, were
observed in SkBr3 and MDA-MB-453 cells expressing
MTSS1 or SCAMP1 compared to cells expressing the
empty vector (Fig. 6a, b). This increase was signiﬁcantly
important when MTSS1 and SCAMP1 were co-expressed
(Fig. 6a, b). To determine whether this event is associated
with MTSS1-mediated activation of RAC1-GTP, we used a
Glutathione resin-based IP system to pull down active
RAC1 (RAC-GTP) from whole-cell extracts that were
obtained from SkBr3 cells transfected with the empty vec-
tor, MTSS1-GFP, SCAMP1-HA or a combination of
MTSS1-GFP and SCAMP1-HA. The immunoprecipitates
were analysed by IB using an antibody for RAC1. MTSS1-
expressing cells showed increased levels of RAC1-GTP
expression as previously reported (Fig. 6c)7. SCAMP1-
expressing cells also showed an increased activity of RAC1-
GTP, similar to the one observed with MTSS1-expressing
cells. However, co-expression of MTSS1 and SCAMP1
resulted in higher expression level of RAC1-GTP when
compared to singularly expressing MTSS1 or
SCAMP1 cells. The increased cell–cell contacts in the
presence of MTSS1 and SCAMP1 and that were observed
by F-actin staining suggests potential increase of cell–cell
adhesions. To determine this, we performed a cell adhesion
assay using the Vybrant™ Cell Adhesion Assay. Indeed,
signiﬁcant increase in cell–cell adhesions were observed in
the presence of MTSS1 and SCAMP1, and when compared
to MTSS1 or SCAMP1 alone, and to the control (Fig. 6d, e).
Although an increase of cell–cell adhesions were observed
in the presence of either MTSS1 or SCAMP1, this increase
was signiﬁcantly lower than the one observed in the pre-
sence of expression of both molecules. Taken together,
these observations highlight the cooperation of MTSS1 and
Scamp1 in preventing HER2+/ER−/PR− cancer progres-
sion and provide further insights on early events associated
with the pathogenesis of cancer invasion.
Discussion
Breast cancer is a heterogeneous disease resulting from a
highly complex and diverse genomic portrait. Clinical
management is determined by clinicopathology assessment,
testing for hormonal (ER/PR) receptors and ampliﬁcation
of HER2. Essentially, this results in patient molecular
classiﬁcation that guides treatment regimen selection and
survival risk. If improvement in individualised treatment is
to be achieved, it is important to gain a better under-
standing of the cell signalling pathways that govern, or
frustrate, patient molecular class membership. Risk of
disease-speciﬁc death is increased by metastasis develop-
ment and treatment resistance; the latter may result from
interacting or opposing cell signalling pathways, calling for
a new combination therapy approach24, to reduce metas-
tasis risk. Metastasis involves a multi-step biological process
and is characterised by loss of cell:cell adhesion, allowing
cancer cells to invade through surrounding tissue25.
Cell–cell adhesions are maintained by functional units
of multi-protein complexes that are organised into three
general classes of proteins; the cell adhesion molecules/
adhesion receptors, the extracellular matrix (ECM) pro-
teins, and the cytoplasmic plaque/peripheral membrane
proteins26. These structures are essential for tissue orga-
nisation, homoeostasis and function. The maintenance
and regulation of this natural and exceptional machinery
rely on a complex network of intracellular and extra-
cellular signals and cellular pathways. During tumour
progression, cell–cell adhesions are affected by cytoske-
leton alterations, disassembly of cell–cell junctions and
consequent changes in cell morphology27,28. This enables
malignant cancer cells to migrate, invade and metastasis.
MTSS1 belongs to the IMD-family (IRSp53 and MIM
(Missing in metastasis) domain) that act as cytoskeletal
scaffold proteins and regulate cytoskeletal dynamics
through interaction with Rac1, actin and actin-associated
proteins5–7,19,29. MTSS1 is highly expressed in primary
tumours and its loss has been found to correlate with
metastasis and poor prognosis in different types of can-
cer9,15–22. However, other studies have shown that
MTSS1 expression may be associated with increased
invasion and metastasis in subtypes of malignant
melanoma, non-small cell lung (NSCLC) and breast
cancer30–32. These observations indicate differences in
functionality for MTSS1 according to tumour speciﬁcity.
Although MTSS1 was expressed in some HER2+ mole-
cular subtypes, we observed its expression was
markedly decreased in clinical tumour samples with the
(see ﬁgure on previous page)
Fig. 4 Cellular Interactions between MTSS1 and SCAMP1 in HER2+/ER−/PR− breast cancer cell lines. a Protein expression proﬁles of
endogenous MTSS1 and SCAMP1 as assessed by immunoblotting from BT-474, SkBr3 and MDA-MB-453 whole-cell extracts and using MTSS1 and
SCAMP1 antibodies. b Proximity ligation analysis of endogenous MTSS1 and SCAMP1 interactions in BT-474 cells. Scale bar= 10μm. The graph
represents the number of dots/cell. Two tailed t-test **p= 0.0024. c Interaction of MTSS1 and SCAMP1 as shown by immunoblotting from anti-MTSS1
immunoprecipitates and from BT-474 whole-cell extracts using anti-MTSS1 and anti-SCAMP1 antibodies. d Schematic representation of MTSS1-GFP
and SCAMP1-HA mutant constructs and their protein expression proﬁles as assessed by immunoblotting from SkBr3 and MDA-MB-453 whole-cell
extracts and using anti-GFP and anti-HA antibodies. e Immunoﬂuorescence images demonstrating expression of MTSS1-GFP and/or SCAMP1-HA in
SkBr3 and MDA-MB-453 cells using anti-GFP and anti-HA antibodies. Scale bar= 10 μm
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Fig. 5 (See legend on next page.)
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HER2+/ER−/PR− phenotype, suggesting hormonal
androgen expression may mitigate for the loss of MTSS1
tumour suppressor functionality. This decrease of MTSS1
expression correlated with reduced survival and worse
prognosis in HER2+/ER−/PR− breast cancer patients.
Furthermore, this clinical ﬁnding was validated in our
in vitro invasive models of breast cancer. We showed that
restoring Mtss1 expression in HER2+/ER−/PR− breast
cancer cell lines promoted cell–cell adhesion and pre-
vented cell invasion. These events were associated with the
capacity of MTSS1 to induce elevated levels of RAC1-
GTP, as previously reported7. Our clinical ﬁndings support
a recent study showing decreased survival in trastuzumab-
treated breast cancer patients with a HER2/ER− tumour
proﬁle compared to HER2/ER+ (HER2/luminal B)
patients33. The current ﬁndings provide a possible expla-
nation for the difference seen in the two patient groups.
Although we have some understanding of the role of
MTSS1 in cancer, cellular pathways that may regulate its
function are not well-known. Using a system biology
approach, we identiﬁed several potential interacting part-
ners, of which SCAMP1 was selected for further studies.
This selection was based on the role of this molecule in
post-Golgi recycling pathways and in endosome cell
membrane recycling10,11. MTSS1 transport to the cell sur-
face may be facilitated by SCAMP1. Moreover, the role of
SCAMP1 in cancer is still unknown. Indeed, we found that
SCAMP1 expression correlated with Mtss1 expression in
tumours with the HER2+/ER−/PR− phenotype and its
expression was decreased similarly to MTSS1 in the HER2
+/ER−/PR− breast cancer class. Likewise, restoring
SCAMP1 expression in HER2+/ER−/PR− breast cancer
cell lines also promoted cell–cell adhesion and prevented
cell invasion. Importantly, co-expression of MTSS1 and
SCAMP1 resulted in a more efﬁcient inhibition of cell
invasion and increased cell–cell adhesion in our cancer
models when compared to the expression of Mtss1 or
Scamp1 alone. Taken together, these results conﬁrm our
hypothesis of synergistic interaction between MTSS1-
mediated and SCAMP1-mediated cellular pathways in
preventing HER2+/ER−/PR− breast cancer invasion. Our
ﬁndings lead us to propose that further investigations are
needed to assess the relationship between loss of MTSS1 in
HER2 patients and its relationship to trastuzumab response.
Materials and methods
Antibodies
For this study, we used antibodies to MTSS1 (1:30 for
IHC, LS-B1818, LifeSpan BioSciences, Seattle, WA, USA),
MTSS1 (1:250 for IB, 4386, Cell Signaling Technology,
Danvers, MA, USA), MTSS1 (1:50 for PLA, sc-101390,
Santa Cruz Biotechnology, Dallas, TX, USA), SCAMP1
(1:25 for IHC, 1:100 for PLA, 15327-1-AP, Proteintech,
Rosemont, IL, USA), SERPIN B13 (1:125 for IHC, NBP2-
01312, Novus Biological, Littleton, CO 80120, USA), GFP
(1:1000, ab1218, Abcam, Cambridge, UK), HA (1:1000 for
IB, 1:200 for IF, A190-108 A, Bethyl Laboratories Inc.,
Montgomery, TX, USA), β-actin (1:5000 for IB, A5441,
Sigma-Aldrich, St Louis, MO, USA).
Plasmids and constructs
MTSS1-GFP and SCAMP1-HA fusion genes were syn-
thesised using custom Gene Synthesis Service (GenScript,
Piscataway, NJ, USA) and incorporated into PUC57Kan
cloning vector. The fusions genes PUC57Kan vector were
further sub-cloned into PCDNA 3.1(+) expression vector
(Invitrogen, ThermoFisher scientiﬁc) using 5′-BamH1
and 3′-Xba I restriction sites. MTSS1-shRNA lentiviral
constructs were purchased from Sigma-Aldrich
(SHCLNG-NM_014751) and were used as previously
described34. SCAMP1 siRNAs were purchased from
QIAGEN (FlexiTube GeneSolution GS9522 for SCAMP1)
and were used following manufacturer recommendations.
Cell lines, growth conditions and cell transfection
SkBr3 breast cancer cells (HTB-20, ATCC) were cultured
in Lonza/12–168 McCoy’s media with 10% fetal bovine
serum (FBS). MDA-MB-453 cells (ACC65, Leibniz Institute
DSMZ-German Collection of Microorganisms and Cell
Cultures) were cultured in 90% Leibovitz’s L-15 medium
with 10% FBS. BT-474 cells (HTB-20, ATCC) were cultured
in ATCC/46-XHBRI-CARE media with 10% FBS and 1.5 g/
L Sodium Bicarbonate. Plasmids were transfected using
Lipofectamine™ 3000 Reagent (L3000001, ThermoFisher
Scientiﬁc) and following manufacturer recommendations.
Cell migration, invasion, proliferation and adhesion assays
For wound-healing assay (Scratch assay), SkBr3 and
MDA-MB-453 cells expressing the empty vector, MTSS1-
(see ﬁgure on previous page)
Fig. 5 MTSS1 and SCAMP1 expression prevents cell migration and invasion. a, b Wound-healing assay (Scratch assay) using SkBr3 and MDA-
MB-453 expressing MTSS1-GFP, SCAMP1-HA or both constructs and the corresponding data quantifying gap closure at time points 0, 24 and 48 h
following scratching. ANOVA ****P= < 0.0001 and ***P= 0.0001. Scale bar= 200 μm. c Wound-healing assay (Scratch assay) using BT-474 cells
expressing empty vector, MTSS1-shRNA, SCAMP1 siRNA or both and the corresponding data quantifying gap closure at time points 24 h following
scratching. ANOVA ***P < 0.0001. d, e Well-cell invasion assay using SkBr3 and MDA-MB-453 cells expressing MTSS1-GFP, SCAMP1-HA or both
constructs and the data relating to the number of invading cells after 48 h of culture. ANOVA ***P= 0.0001 and ANOVA **P= 0.0084. Scale bar= 10
μm. f, g Graphs representing measurements of cell proliferation of SkBr3 and MDA-MB-453 expressing MTSS1-GFP, SCAMP1-HA or both constructs (24
and 48 h post transfection). Two-way ANOVA P(ns)= 0.1878) and two-way ANOVA P(ns)= 0.8040
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GFP, SCAMP1-HA or both were cultured to 80% con-
ﬂuence and serum starved for 24 h, after which a scratch
was made in the middle of each well using a 10 μl pipette
tip. Images from triplicate experiments at 0, 24 and 48 h
were taken and the distances between the edges of the
scratch were measured at 3 different points using Carl
Zeiss AxioVision software35 (Buczek et al., 2016). The
measurements were expressed as percentages of gap clo-
sure. For the well-cell invasion assay, we used the col-
orimetric QCM ECMatrix Cell Invasion Assay (ECM550,
Millipore, Ltd.) and the cell count of invasive cancer cells
were performed following the manufacturer’s recom-
mendations. For the proliferation assay, cells were cul-
tured (10000 cells per/well) and then transfected for 24 h
and 48 h. Media were removed and the proliferation was
assessed using the CyQUANT® NF Cell Proliferation
Assay Kit (C35007, Life Technologies, Ltd.) and following
the manufacturer’s recommendations. Cell–cell adhesions
were assessed following transfections (48 h) and using
Vybrant™ Cell Adhesion Assay Kit (V13181, Fisher Sci-
entiﬁc), and the manufacturer’s recommendations.
IB and IP
The experimental procedures were performed as
described previously34. For IB, the cells lysed in 1× solu-
tion containing 50 mM Tris-HCl (pH 6.8), 100mM
dithiothreitol, 2% (w/v) SDS, 0.1% (w/v) bromophenol
blue, and 10% (v/v) glycerol, and loaded onto Tris/glycine
SDS–polyacrylamide gels for electrophoresis. The pro-
teins were transferred onto Amersham Hybond-P PVDF
Fig. 6 MTSS1 and SCAMP1 expression promotes cell–cell adhesions via promoting the expression of active RAC1. a, b Immunoﬂuorescence
images showing expression of F-actin, MTSS1-GFP and/or SCAMP1-HA in SkBr3 and MDA-MB-453 cells expressing MTSS1-GFP, SCAMP1-HA or both
constructs and using Alexa Fluor® 568 Phalloidin, anti-GFP and anti-HA antibodies. Scale bar= 10 μm. c Immunoblotting from GST-PAK1-PBD pull
down of RAC1 and from transfected SkBr3 and MDA-MB-453 whole-cell extracts using RAC1− antibody. d, e Graphs representing measurements
from cell adhesion assays performed on SkBr3 and MDA-MB-453 expressing the empty vector, MTSS1-GFP, SCAMP1-HA or both constructs (48 h post
transfection). ANOVA ****P < 0.0001) and ANOVA ****P < 0.0001
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membranes (GE Healthcare). Membranes were blocked
with 10% (w/v) Marvel milk powder/phosphate-buffered
saline (PBS) solution with 0.1% (v/v) Tween-20 (PBST).
Membranes were washed in PBST, membranes were
incubated with primary antibodies (in blocking solution)
overnight at 4 °C followed by washing and incubation with
secondary antibodies for 1 h at room temperature prior to
visualisation using Clarity™ Western ECL Substrate (Bio-
Rad Laboratories) and a CCD camera (SynGene). For IP,
the cells were lysed in IP buffer (0.05M Tris pH 7.4, 0.15
M NaCl, 0.5% (v/v) Triton X-100, and 0.001M EDTA).
The extracts were pre-cleared for 1 h at 4 °C using Protein
G Plus-Agarose beads (IP08, Calbiochem) and corre-
sponding IgG. GFP antibody was incubated with agarose
beads in IP buffer for 2 h before adding the pre-cleared
extracts for overnight IP. The beads were washed 4 times
in IP buffer and suspended in lysis buffer, after which
samples were analysed by IB. For active Rac1 detection,
we used the Active Rac1 Detection Kit and following
manufacturer recommendations (#8815, Cell Signaling
Technology).
Bioinformatics analysis
Monte Carlo Cross validation
Prior to ANN training, the data was randomly divided
into three subsets; 60% for training, 20% for testing (to
assess model performance during the training process)
and 20% for validation (to independently test the model
on data completely blind to the model). This process of
random sample cross validation also contributed to the
reduction of over ﬁtting to the data.
Architecture
The ANN modelling undertaken used a supervised
learning approach applied to a three-layer multi-layer
perceptron architecture. The initial weights matrix was
randomised with a standard deviation of 0.1 to reduce the
risk of over ﬁtting the data. The ANN architecture was
initially constrained to two hidden nodes in the hidden
layer also for this reason. Hidden nodes and the output
node incorporated a sigmoidal transfer function. During
training, weights were updated by a feed-forward back
propagation algorithm36. Learning rate and momentum
were set at 0.1 and 0.5, respectively. The output node was
coded as 0 if the patient showed low expression of RAS,
and 1 if the patient showed high expression of RAS.
Network inference analysis
Network inference analysis was undertaken on the
top 100 probes from step 1 of the classiﬁer development.
Thus the single non-orthogonal probes were analysed. This
approach13,14 uses a suite of ANN models to study
the inter-relationship between markers in a deﬁned set. In
the algorithm all markers are used to predict 1 marker and
the weights of the model analysed. This is then repeated for
each marker in turn so that in the process all markers are
used as outputs and a matrix of interactions identiﬁed. This
matrix is then ﬁltered to identify the strongest interactions
and the most connected/inﬂuential genes. The resulting
interactions were presented using Cytoscape.
Immunohistochemistry
The relationship between MTSS1 to its carrier molecule,
SCAMP1, and its stabilisation protein, SERPIN B13 was
investigated in a cohort of wax embedded tissue micro-
arrayed (TMA) breast cancer using immunohistochem-
istry. The TMA comprises tumour samples obtained from
unselected patients diagnosed with primary operable breast
cancer (TNM stage I-IIIa) that presented at the Notting-
ham Breast Unit between 1988 and 1998. Prospectively
collected clinical and pathology data is available including
development of recurrence and distant metastases (DM),
survival time and disease-free interval (DFI). Breast cancer-
speciﬁc survival (BCSS) was deﬁned as the time (in
months) from the date of the primary surgical treatment to
the time of death from breast cancer. DFI was deﬁned as
the interval (in months) from the date of the primary
surgical treatment to the ﬁrst locoregional or distant
metastasis. Patient management and treatment regimens
have been previously described1. Protein expression was
immunohistochemically assessed using a Ventana Bench-
mark Ultra platform (Roche Group, Arizona, US). Malig-
nant epithelium was microscopically dichotomously scored
for levels of staining intensity where 0: negative or low
intensity staining, and 1: moderate to strong intensity.
REMARK guidelines37 were used in the whole patient
series and the number of scorable patients was found to be
less than those originally arrayed due to tissue detachment
and absence of malignant tissue. A Pearson's χ2-test with
cross-tabulation tables was performed to assess associa-
tions between the biomarkers and clinical survival data,
using SPSS (Version 21; IBM, US). Kaplan–Meier plots
with log-rank tests were used to model biomarker asso-
ciations for disease-speciﬁc survival (DSS) and time to
metastasis development. χ2-tests were performed on the
whole (unselected) patient cohort, followed by subset
analysis of HER2 (cerbB2)-positive patients, and Pearson's
correlation tests were used to assess the association
between different antigen biomarkers with clinical out-
come. HER2+ patients were stratiﬁed according to hor-
monal oestrogen and progesterone receptor status.
IF staining and PLA
The IF staining was performed as previously descri-
bed34. Cells were ﬁxed in 4% (w/v) paraformaldehyde and
then treated as follows: the sections or cancer cells were
washed three times in 1× PBS for 10min each, blocked
and permeabilised in 10% (w/v) bovine serum albumin in
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0.1% (v/v) PBS-Tween, incubated overnight with primary
antibody (in blocking solution), washed three times for 10
min each with 1× PBS, incubated for 1 h with secondary
antibody (in blocking solution) and washed three times
with 1× PBS. Sections and melanoma cells were coun-
terstained and mounted with DAPI ﬂuorescent medium
(Vector Laboratories) for IF microscopy. The PLA assay
was performed using the Duolink® In Situ Red Starter Kit
Mouse/Rabbit (DUO92101, Sigma-Aldrich, St Louis, MO,
USA) and following the manufacturer recommendations.
The number of dots/cell was determined by counting the
number of dots from three independent images.
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